Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
Notes underwriting agrmnt
|
|
Ayala Pharmaceuticals, Inc. (ADXS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/28/2021 |
GN
| Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting |
| 04/26/2021 |
GN
| UPDATE - Advaxis Announces Achievement of Second Milestone Under ADXS-HER2 Licensing Agreement with OS Therapies |
| 04/26/2021 |
GN
| Advaxis Announces Receipt of Second Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies |
| 03/23/2021 |
GN
| Advaxis to Present Corporate Overview at the Benzinga Biotech Small Cap Conference |
| 03/16/2021 |
GN
| Advaxis Reports First Quarter Ended January 31, 2021 Financial Results and Provides a Business Update |
| 03/12/2021 |
GN
| Advaxis to Present at the American Association for Cancer Research (AACR) 2021 Annual Meeting |
| 01/25/2021 |
GN
| Advaxis Reports Fiscal Year 2020 Financial Results and Provides a Business Update |
| 01/19/2021 |
GN
| Advaxis Announces Receipt of Funding Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies |
| 12/22/2020 |
GN
| Advaxis Announces Listing Transfer to Nasdaq Capital Market and Additional 180-day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule |
| 11/23/2020 |
GN
| Advaxis, Inc. Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock |
| 11/09/2020 |
GN
| Advaxis Presents Updated Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting |
| 09/24/2020 |
GN
| Advaxis Announces FDA Clearance of New IND for ADXS-504 for Treatment of Prostate Cancer |
| 09/10/2020 |
GN
| Advaxis Reports Third Quarter Ended July 31, 2020 Financial Results and Provides a Business Update |
| 09/04/2020 |
GN
| Advaxis Announces Resignation of Chief Financial Officer |
| 06/11/2020 |
GN
| Advaxis Reports Second Quarter Ended April 30, 2020 Financial Results and Provides a Business Update |
| 06/01/2020 |
GN
| Advaxis to Host Second Quarter Financial Results and Business Update Conference Call on Thursday, June 11, 2020 |
| 03/13/2020 |
GN
| Advaxis Reports First Quarter Ended January 31, 2020 Financial Results and Provides a Pipeline Update |
| 03/03/2020 |
GN
| Advaxis to Present at the 2020 LD Micro Virtual Conference |
| 02/27/2020 |
GN
| Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at I/O 360° Conference |
| 01/30/2020 |
GN
| Data on Advaxis' Clinical Programs to be Presented at Upcoming Medical Meetings |
| 08/12/2019 |
GN
| BriaCell Appoints Richard J. Berman to Board of Directors |
| 04/03/2019 |
GN
| Market Trends Toward New Normal in The TJX Companies, Tronox, Service Corporation International, Southwest Gas, Advaxis, and International Seaways — Emerging Consolidated Expectations, Analyst Ratings |
| 10/18/2018 |
GN
| Investor Expectations to Drive Momentum within Aethlon Medical, Jaguar Animal Health, Advaxis, Forestar Group, Platform Specialty Products, and AVEO Pharmaceuticals — Discovering Underlying Factors of Influence |
| 08/28/2018 |
GN
| Recent Analysis Shows Liberty TripAdvisor, Control4, Ferro, Advaxis, Frontier Communications, and Newpark Resources Market Influences — Renewed Outlook, Key Drivers of Growth |
| 11/22/2017 |
GN
| Analysis: Positioning to Benefit within Diebold, Liberty TripAdvisor, Paycom Software, First American, Advaxis, and Sanmina — Research Highlights Growth, Revenue, and Consolidated Results |
| 04/19/2017 |
GN
| Advaxis Appoints Anthony Lombardo as Chief Business Officer |
| 03/27/2017 |
GN
| Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac |
| 03/15/2017 |
GN
| Advaxis Presents Oral Late-breaking Data on Phase 2 GOG-0265 Study of Axalimogene Filolisbac at SGO's Annual Meeting on Women's Cancer |
| 03/15/2017 |
GN
| Advaxis Presents Oral Late-breaking Data on Phase 2 GOG-0265 Study of Axalimogene Filolisbac at SGO's Annual Meeting on Women's Cancer |
| 03/13/2017 |
GN
| Advaxis to Present at the 2017 Barclays Global Healthcare Conference |
| 03/06/2017 |
GN
| Advaxis Announces FDA Acceptance of IND for Groundbreaking Personalized Neoepitope Immunotherapy, ADXS-NEO |
| 02/27/2017 |
GN
| Advaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy |
| 02/06/2017 |
GN
| Advaxis Announces First Patient Dosed in Global Phase 3 AIM2CERV Trial for High-risk, Locally Advanced Cervical Cancer |
| 01/30/2017 |
GN
| GOG-0265 Study in Metastatic Cervical Cancer Selected for Late-Breaking Data Presentation at the Society of Gynecologic Oncology's Annual Meeting on Women's Cancer |
|
|